Evidence map›Paper›PMID 32116106›Full record

ArticleCancer biology & therapy2020

Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma.

Andres F Correa, Karen J Ruth, Tahseen Al-Saleem, Jianming Pei, Essel Dulaimi, Debra Kister, Michelle Collins, Phillip H Abbosh, Michael J Slifker, Eric Ross and 2 more

Abstract read
In one paragraph

Article in Cancer biology & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andres F CorreaDepartment of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Karen J RuthDepartment of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Tahseen Al-SaleemDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Jianming PeiGenomics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.
Essel DulaimiDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Debra KisterDepartment of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Michelle CollinsDepartment of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Phillip H AbboshMolecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Michael J SlifkerDepartment of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Eric RossDepartment of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Robert G UzzoDepartment of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Joseph R TestaGenomics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurement of a tumor's overall genomic instability has gathered recent interest over the identification of specific genomic imbalances, as it may provide a more robust measure of tumor aggressiveness. Here we demonstrate the association of tumor genomic instability in the prediction of disease recurrence in patients with clinically localized clear cell renal cell carcinoma (ccRCC). Genomic copy number analysis was performed using SNP-based microarrays on tumors from 103 ccRCC patients. The number of copy number alterations (CNAs) for each tumor was calculated, and a genomic imbalance threshold (GIT) associated with high stage and high-grade disease was determined. Cox proportional hazards regression analyzes were performed to assess the effect of GIT on recurrence-free survival adjusting for known confounders. In the cohort, copy number losses in chromosome arms 3p, 14q, 6q, 9p, and 1p and gains of 5q and 7p/q were common. CNA burden significantly increased with increasing stage (

Indexed as

DNA Copy Number VariationsGenomic InstabilityPolymorphism, Single NucleotideAdenocarcinoma, Clear CellAdultAgedAged, 80 and overDisease ProgressionFemaleHumansKidney NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisSurvival Ratedna copy number analysisgenomic imbalancesKidney cancerrecurrence-free survival

Identifiers

PMID32116106
PMCPMC7515487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.